FDA approves first biosimilar for cancer

FDA approved a BLA from Amgen Inc. (NASDAQ:AMGN) for Mvasi bevacizumab-awwb (ABP 215), a biosimilar of cancer drug Avastin bevacizumab. FDA said Mvasi is the first biosimilar approved in the U.S. to treat cancer.

Mvasi is approved for all of the cancer types on Avastin's label, except ovarian cancer. Specifically, the biosimilar is indicated to treat adults with metastatic colorectal cancer (CRC), metastatic renal cell carcinoma (RCC), non-squamous non-small cell lung cancer (NSCLC), glioblastoma and cervical cancer...